Nat Commun:e2型APOE对神经退行性疾病具有保护作用

2020-09-24 xiaozeng MedSci原创

载脂蛋白E(ApoE)是大脑中一个重要的脂转运蛋白。其合成由编码基因APOE第4个外显子的两个基因位点上的三个等位基因所控制,因此一共会产生三个单倍型和六个基因型:e2、e3、e4三种构体。其中,在晚

载脂蛋白E(ApoE)是大脑中一个重要的脂转运蛋白。其合成由编码基因APOE第4个外显子的两个基因位点上的三个等位基因所控制,因此一共会产生三个单倍型和六个基因型:e2、e3、e4三种构体。其中,在晚期阿尔茨海默症(AD)患者中,e4型是主要的风险构体。相反的,e2则是主要常见的保护构体。

在该研究中,研究人员通过NACC(The National Alzheimer's Coordinating Center ,国家阿尔茨海默病症协调中心)数据库获取1557个大脑样本数据(其中包括130个e2携带者和679个e4携带者),通过检测APOE e2构体与多种神经退行性病变的关联,以探究其潜在的神经保护作用。

APOE基因型与淀粉样蛋白和tau神经病理学的关系

AD相关的淀粉样斑和Braak分级病理分析显示,相比于e3/e3和e4携带者,e2携带者具有更高且更显著的保护作用。令人意外的是,e2/e4携带者的AD病理风险与e4携带者(而非e2携带者)相似。在额颞叶多发性病变和Tau蛋白病变(tauopathies)的分析中,e2构体无病理学显著相关性。

APOE e2/e4基因型与Braak分级的关系

总而言之,该研究显示APOE e2对于神经退行性疾病具有较高但限制性的保护作用。


原始出处:

Goldberg, T.E., Huey, E.D. & Devanand, D.P. Association of APOE e2 genotype with Alzheimer’s and non-Alzheimer’s neurodegenerative pathologies. Nat Commun 11, 4727 (18 September 2020).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1884681, encodeId=c887188468149, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 14 21:20:46 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957183, encodeId=c71d195e18329, content=<a href='/topic/show?id=5879e458629' target=_blank style='color:#2F92EE;'>#神经退行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74586, encryptionId=5879e458629, topicName=神经退行)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed May 19 23:20:46 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735406, encodeId=7e7e1e35406d3, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Thu Dec 24 13:20:46 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087783, encodeId=a5bd208e78321, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 01 00:20:46 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590611, encodeId=3c721590611c4, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Sat Sep 26 12:20:46 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599139, encodeId=cd8a15991395f, content=<a href='/topic/show?id=f14d2e187ac' target=_blank style='color:#2F92EE;'>#保护作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27187, encryptionId=f14d2e187ac, topicName=保护作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ee918684940, createdName=photoman, createdTime=Sat Sep 26 12:20:46 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888084, encodeId=dca3888084a5, content=非常喜欢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/5d0d7c713a994e1494cd314141e005b6/30649e163a8e434b89e83aed5cc300b3.jpg, createdBy=19395421393, createdName=ms7000001997358761, createdTime=Thu Sep 24 22:12:56 CST 2020, time=2020-09-24, status=1, ipAttribution=)]
    2021-05-14 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1884681, encodeId=c887188468149, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 14 21:20:46 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957183, encodeId=c71d195e18329, content=<a href='/topic/show?id=5879e458629' target=_blank style='color:#2F92EE;'>#神经退行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74586, encryptionId=5879e458629, topicName=神经退行)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed May 19 23:20:46 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735406, encodeId=7e7e1e35406d3, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Thu Dec 24 13:20:46 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087783, encodeId=a5bd208e78321, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 01 00:20:46 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590611, encodeId=3c721590611c4, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Sat Sep 26 12:20:46 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599139, encodeId=cd8a15991395f, content=<a href='/topic/show?id=f14d2e187ac' target=_blank style='color:#2F92EE;'>#保护作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27187, encryptionId=f14d2e187ac, topicName=保护作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ee918684940, createdName=photoman, createdTime=Sat Sep 26 12:20:46 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888084, encodeId=dca3888084a5, content=非常喜欢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/5d0d7c713a994e1494cd314141e005b6/30649e163a8e434b89e83aed5cc300b3.jpg, createdBy=19395421393, createdName=ms7000001997358761, createdTime=Thu Sep 24 22:12:56 CST 2020, time=2020-09-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1884681, encodeId=c887188468149, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 14 21:20:46 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957183, encodeId=c71d195e18329, content=<a href='/topic/show?id=5879e458629' target=_blank style='color:#2F92EE;'>#神经退行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74586, encryptionId=5879e458629, topicName=神经退行)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed May 19 23:20:46 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735406, encodeId=7e7e1e35406d3, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Thu Dec 24 13:20:46 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087783, encodeId=a5bd208e78321, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 01 00:20:46 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590611, encodeId=3c721590611c4, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Sat Sep 26 12:20:46 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599139, encodeId=cd8a15991395f, content=<a href='/topic/show?id=f14d2e187ac' target=_blank style='color:#2F92EE;'>#保护作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27187, encryptionId=f14d2e187ac, topicName=保护作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ee918684940, createdName=photoman, createdTime=Sat Sep 26 12:20:46 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888084, encodeId=dca3888084a5, content=非常喜欢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/5d0d7c713a994e1494cd314141e005b6/30649e163a8e434b89e83aed5cc300b3.jpg, createdBy=19395421393, createdName=ms7000001997358761, createdTime=Thu Sep 24 22:12:56 CST 2020, time=2020-09-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1884681, encodeId=c887188468149, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 14 21:20:46 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957183, encodeId=c71d195e18329, content=<a href='/topic/show?id=5879e458629' target=_blank style='color:#2F92EE;'>#神经退行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74586, encryptionId=5879e458629, topicName=神经退行)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed May 19 23:20:46 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735406, encodeId=7e7e1e35406d3, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Thu Dec 24 13:20:46 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087783, encodeId=a5bd208e78321, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 01 00:20:46 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590611, encodeId=3c721590611c4, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Sat Sep 26 12:20:46 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599139, encodeId=cd8a15991395f, content=<a href='/topic/show?id=f14d2e187ac' target=_blank style='color:#2F92EE;'>#保护作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27187, encryptionId=f14d2e187ac, topicName=保护作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ee918684940, createdName=photoman, createdTime=Sat Sep 26 12:20:46 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888084, encodeId=dca3888084a5, content=非常喜欢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/5d0d7c713a994e1494cd314141e005b6/30649e163a8e434b89e83aed5cc300b3.jpg, createdBy=19395421393, createdName=ms7000001997358761, createdTime=Thu Sep 24 22:12:56 CST 2020, time=2020-09-24, status=1, ipAttribution=)]
    2020-11-01 liuli5079
  5. [GetPortalCommentsPageByObjectIdResponse(id=1884681, encodeId=c887188468149, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 14 21:20:46 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957183, encodeId=c71d195e18329, content=<a href='/topic/show?id=5879e458629' target=_blank style='color:#2F92EE;'>#神经退行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74586, encryptionId=5879e458629, topicName=神经退行)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed May 19 23:20:46 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735406, encodeId=7e7e1e35406d3, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Thu Dec 24 13:20:46 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087783, encodeId=a5bd208e78321, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 01 00:20:46 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590611, encodeId=3c721590611c4, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Sat Sep 26 12:20:46 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599139, encodeId=cd8a15991395f, content=<a href='/topic/show?id=f14d2e187ac' target=_blank style='color:#2F92EE;'>#保护作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27187, encryptionId=f14d2e187ac, topicName=保护作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ee918684940, createdName=photoman, createdTime=Sat Sep 26 12:20:46 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888084, encodeId=dca3888084a5, content=非常喜欢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/5d0d7c713a994e1494cd314141e005b6/30649e163a8e434b89e83aed5cc300b3.jpg, createdBy=19395421393, createdName=ms7000001997358761, createdTime=Thu Sep 24 22:12:56 CST 2020, time=2020-09-24, status=1, ipAttribution=)]
    2020-09-26 xiongke016
  6. [GetPortalCommentsPageByObjectIdResponse(id=1884681, encodeId=c887188468149, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 14 21:20:46 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957183, encodeId=c71d195e18329, content=<a href='/topic/show?id=5879e458629' target=_blank style='color:#2F92EE;'>#神经退行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74586, encryptionId=5879e458629, topicName=神经退行)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed May 19 23:20:46 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735406, encodeId=7e7e1e35406d3, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Thu Dec 24 13:20:46 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087783, encodeId=a5bd208e78321, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 01 00:20:46 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590611, encodeId=3c721590611c4, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Sat Sep 26 12:20:46 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599139, encodeId=cd8a15991395f, content=<a href='/topic/show?id=f14d2e187ac' target=_blank style='color:#2F92EE;'>#保护作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27187, encryptionId=f14d2e187ac, topicName=保护作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ee918684940, createdName=photoman, createdTime=Sat Sep 26 12:20:46 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888084, encodeId=dca3888084a5, content=非常喜欢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/5d0d7c713a994e1494cd314141e005b6/30649e163a8e434b89e83aed5cc300b3.jpg, createdBy=19395421393, createdName=ms7000001997358761, createdTime=Thu Sep 24 22:12:56 CST 2020, time=2020-09-24, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1884681, encodeId=c887188468149, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 14 21:20:46 CST 2021, time=2021-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957183, encodeId=c71d195e18329, content=<a href='/topic/show?id=5879e458629' target=_blank style='color:#2F92EE;'>#神经退行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74586, encryptionId=5879e458629, topicName=神经退行)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Wed May 19 23:20:46 CST 2021, time=2021-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735406, encodeId=7e7e1e35406d3, content=<a href='/topic/show?id=740394686b2' target=_blank style='color:#2F92EE;'>#退行性疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94686, encryptionId=740394686b2, topicName=退行性疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0233899115, createdName=ZGMFX35A, createdTime=Thu Dec 24 13:20:46 CST 2020, time=2020-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087783, encodeId=a5bd208e78321, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sun Nov 01 00:20:46 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590611, encodeId=3c721590611c4, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Sat Sep 26 12:20:46 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599139, encodeId=cd8a15991395f, content=<a href='/topic/show?id=f14d2e187ac' target=_blank style='color:#2F92EE;'>#保护作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27187, encryptionId=f14d2e187ac, topicName=保护作用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ee918684940, createdName=photoman, createdTime=Sat Sep 26 12:20:46 CST 2020, time=2020-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888084, encodeId=dca3888084a5, content=非常喜欢, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200924/5d0d7c713a994e1494cd314141e005b6/30649e163a8e434b89e83aed5cc300b3.jpg, createdBy=19395421393, createdName=ms7000001997358761, createdTime=Thu Sep 24 22:12:56 CST 2020, time=2020-09-24, status=1, ipAttribution=)]
    2020-09-24 ms7000001997358761

    非常喜欢

    0

相关资讯

靶向Aβ的阿尔茨海默症新药BAN2401,开始III期临床研究

BAN2401是抗淀粉样蛋白(Aβ)的抗体,旨在选择性结合后中和并清除有毒的Aβ蛋白。

Cell:髓系细胞免疫信号枢纽——TREM2

阿尔茨海默症,肥胖相关的代谢综合症和肿瘤是当今导致死亡的主要原因。 最新的研究表明,在这些疾病情况下, TREM2作为病理学诱导的免疫信号枢纽,可响应组织损伤,并进行免疫重塑。

Acta Neuropathol:基因新疗法拍了拍你,可逆转阿尔茨海默症相关的记忆力丧失

如今,阿尔茨海默症(AD)已成为全球公共卫生和社会难题。数据表明,每隔3秒,世界上就会多一位AD患者。截至2018年,全球AD患者总数已经超过5000万,而到2050年,这个数字预计将超过1.5亿。

Eisai和Biogen正在向FDA申请aducanumab治疗阿尔茨海默症的优先审查

制药公司百健(Biogen)和卫材(Eisai)近日表示,FDA接受了aducanumab治疗阿尔茨海默症优先审查的申请,并将目标行动日期定为明年3月7日。

大麻素!或是治疗阿尔茨海默症的希望,FDA已批准开展I期临床试验

经大麻素治疗的患有阿尔茨海默氏症转基因小鼠的记忆力得到显著改善。

Mol Psychiatry:英国科学家发现阿尔茨海默症抑制基因,并开发快速药物测试平台

导言:阿尔茨海默症是老年期最为常见的一种痴呆类型,也是老年期最常见的慢性疾病之一。每3秒全世界就会增加1名阿尔茨海默症患者,每100位60岁及以上人口中就有5-8名阿尔茨海默症患者。该病的病因仍未明确